Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The inspections concluded with no Form 483 observations or significant critical findings
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
A five-day inspection was concluded successfully with no critical and no major observations raised
The inspection was concluded with few procedural observations
Subscribe To Our Newsletter & Stay Updated
